banner

Cellceutix Forwards Cancer Drug Study Protocol to Clinical Site

Cellceutix Corporation (CTIX)

Cellceutix Corporation (CTIX)

Cellceutix Corporation (OTCQB: CTIX) is pleased to report that it has submitted for review the “Investigator’s Brochure and Clinical Protocol” sections of its Investigational New Drug (IND) application for Kevetrin™, Cellceutix’s drug in development as a treatment for cancers, to the world-renowned hospital in which it expects to host its Phase I clinical trials. Upon review by the cancer center, Cellceutix will add the documents to the IND for submission to the FDA.

Leo Ehrlich, CEO of Cellceutix, stated,

“I would like to congratulate the Cellceutix team including our many consultants, shareholders, and vendors on this important event. Yes, many thought it was impossible to accomplish what we have achieved. Not only have we have created a new chemical class and breakthrough in medicine; we completed this at amazing speed, about three years, and expect shortly to file our IND. We are working diligently to see Cellceutix flourish and believe the best is yet to come.”

Cellceutix Corporation (CTIX) Stock Quote and News:


0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

MEDL Mobile Partner DJ Pauly D Nominated for Best App Ever Award $MEDL(0)

Mobile app developer MEDL Mobile, Inc. (OTCBB:MEDL) reported that partner DJ Pauly D’s app “Beat That Boardwalk” has been nominated for the 2011 Best Music Game for Android at The Best App Ever Awards (http://bestappever.com/v/mzgm) by the popular app review site. MEDL Mobile Co-Founder Dave Swartz said, “We wanted to do something unexpected for DJ

NexCore Healthcare Capital Leading Percentage Gainers on the OTCBB Today $NXHC(0)

With one hour remaining before today’s closing bell, a look at today’s percentage gainers on the Over the Counter Bulletin Board: NexCore Healthcare Capital Corp. (OTCBB:NXHC) is up 483.09% to $0.20 on 9.1k in volume China Advanced Technology (OTCBB:CADT) is up 234.71% to $4.05 on 300k in volume AISYSTEMS, Inc. (OTCBB:ASYI) is up 147.06% to

Platinum Studios and Mark Canton Partner for “Atlantis Rising” Film Series $PDOS(0)

Platinum Studios Inc. (OTCBB:PDOS) and producer/Platinum Studios Board Member Mark Canton announced that they will be teaming-up to immediately begin work on bringing the Platinum Studios comic book “Atlantis Rising” into an ongoing franchise for the silver screen.  The film is set against an undersea civilization that began over 10,000 years ago, and whose presence

Cannabis Science Updates Show Cannabis Extracts Killing Skin Cancer $CBIS(0)

Following news in December 2011 of a second cancer patient self-administering cannabis extract to combat basal cell carcinoma (skin cancer), Cannabis Science, Inc. (OTCBB:CBIS) reported today that it appears that the cannabis therapy has eradicated the cancer.  The company stated that they are waiting for a full biopsy report to confirm that the cancer is

Bebida Beverage Bringing Koma Unwind to New York City $BBDA(0)

Relaxation Drink “Koma Unwind” will be available to people in the New York City area, according to manufacturer Bebida Beverage Company (Pink Sheets:BBDA).  The company reported this morning that it has signed new agreements with S.K.I. Beer and All Star Imports to distribute the non-alcoholic drink throughout the NYC vicinity. S.K.I. will be rolling-out Koma

read more

Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.